GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Piotroski F-Score

Sunesis Pharmaceuticals (FRA:RYIS) Piotroski F-Score : 0 (As of May. 12, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sunesis Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sunesis Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Sunesis Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Sunesis Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Piotroski F-Score Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 1.00 3.00 3.00 4.00

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 5.00 5.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec20) TTM:Last Year (Dec19) TTM:
Net Income was -5.226 + -5.674 + -3.938 + -3.951 = €-18.79 Mil.
Cash Flow from Operations was -5.198 + -5.145 + -3.598 + -4.655 = €-18.60 Mil.
Revenue was 0.109 + 0 + 0 + 0 = €0.11 Mil.
Gross Profit was 0.109 + 0 + 0 + 0 = €0.11 Mil.
Average Total Assets from the begining of this year (Dec19)
to the end of this year (Dec20) was
(33.516 + 28.496 + 22.649 + 23.8 + 19.109) / 5 = €25.514 Mil.
Total Assets at the begining of this year (Dec19) was €33.52 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €18.20 Mil.
Total Current Liabilities was €2.72 Mil.
Net Income was -5.186 + -5.523 + -5.395 + -4.758 = €-20.86 Mil.

Revenue was 0 + 0 + 0 + 1.866 = €1.87 Mil.
Gross Profit was 0 + 0 + 0 + 1.866 = €1.87 Mil.
Average Total Assets from the begining of last year (Dec18)
to the end of last year (Dec19) was
(13.47 + 24.562 + 18.624 + 37.782 + 33.516) / 5 = €25.5908 Mil.
Total Assets at the begining of last year (Dec18) was €13.47 Mil.
Long-Term Debt & Capital Lease Obligation was €0.25 Mil.
Total Current Assets was €32.69 Mil.
Total Current Liabilities was €8.47 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sunesis Pharmaceuticals's current Net Income (TTM) was -18.79. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sunesis Pharmaceuticals's current Cash Flow from Operations (TTM) was -18.60. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec19)
=-18.789/33.516
=-0.56059792

ROA (Last Year)=Net Income/Total Assets (Dec18)
=-20.862/13.47
=-1.54877506

Sunesis Pharmaceuticals's return on assets of this year was -0.56059792. Sunesis Pharmaceuticals's return on assets of last year was -1.54877506. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sunesis Pharmaceuticals's current Net Income (TTM) was -18.79. Sunesis Pharmaceuticals's current Cash Flow from Operations (TTM) was -18.60. ==> -18.60 > -18.79 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=0/25.514
=0

Gearing (Last Year: Dec19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec18 to Dec19
=0.245/25.5908
=0.00957375

Sunesis Pharmaceuticals's gearing of this year was 0. Sunesis Pharmaceuticals's gearing of last year was 0.00957375. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec20)=Total Current Assets/Total Current Liabilities
=18.202/2.721
=6.68945241

Current Ratio (Last Year: Dec19)=Total Current Assets/Total Current Liabilities
=32.69/8.474
=3.85768232

Sunesis Pharmaceuticals's current ratio of this year was 6.68945241. Sunesis Pharmaceuticals's current ratio of last year was 3.85768232. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sunesis Pharmaceuticals's number of shares in issue this year was 5.179. Sunesis Pharmaceuticals's number of shares in issue last year was 3.188. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.109/0.109
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.866/1.866
=1

Sunesis Pharmaceuticals's gross margin of this year was 1. Sunesis Pharmaceuticals's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec19)
=0.109/33.516
=0.00325218

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec18)
=1.866/13.47
=0.13853007

Sunesis Pharmaceuticals's asset turnover of this year was 0.00325218. Sunesis Pharmaceuticals's asset turnover of last year was 0.13853007. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sunesis Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Sunesis Pharmaceuticals  (FRA:RYIS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sunesis Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines